Trial Profile
Randomized Phase III trial: Maintenance therapy with the monoclonal chimeric antibody rituximab compared to observation in patients with CD20+ B-cell Non-Hodgkins lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 12 Jun 2011 Final results presented at the 16th Congress of the European Hematology Association.
- 12 Mar 2009 Status changed from not stated to completed.
- 01 Jan 2009 Results were published in the Annals of Hematology.